Menu Search
Equities

Beijing Airdoc Technology Co Ltd

2251:HKG.HZ

Beijing Airdoc Technology Co Ltd

Actions
  • Price (HKD)15.48
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+4.59%
  • Beta--
Data delayed at least 15 minutes, as of Apr 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beijing Airdoc Technology Co Ltd is a China-based company that provides AI-empowered retina-based early detection, diagnosis and health risk assessment solutions. The Company's main product is Airdoc-AIFUNDUS 1.0. The Company's product can be used in the diagnosis of glaucoma, cataract, ICVD and ASCVD, diabetic retinopathy of pregnancy, hypertensive retinopathy of pregnancy and other diseases. In addition, the Company has developed a deep pipeline of other Software-as-a-medical devices (SaMDs) and health risk assessment solutions to address various healthcare needs for the whole population, including hospitals, community clinics, health checkup centers, insurance companies, optometry centers and pharmacies.

  • Revenue in HKD (TTM)220.61m
  • Net income in HKD-143.35m
  • Incorporated2015
  • Employees339.00
  • Location
    Beijing Airdoc Technology Co LtdRoom 21, 4th Floor, Building 2A2 Yard, West Third Ring North RoadHaidian DistrictBeijing 100000ChinaCHN
  • Phone+86 1 082362300
  • Websitehttps://www.airdoc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		2251:HKG since
announced		Transaction
value
Beijing Zhitong Technology Co LtdAnnounced19 May 202319 May 2023Announced35.79%25.87m
Data delayed at least 15 minutes, as of Apr 17 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.